Please login to the form below

The hidden costs of poor translation quality and service

How to ensure that outsourcing really adds up to cost-saving
There are many challenges in organising clinical trials - translation should not be one of them! Many CRO project managers complain that their current translation supplier gives them low quality translations and poor service.

Examples quoted include inconsistent translation of the same phrase through a set of documents (probably due to multiple translators being used and the proofreader not ensuring consistency), and documents being returned as stand-alone translations rather than translation tables, meaning that the CRO project managers (PMs) have to align source and target to workout which sentence equates to which.

However, there is often a different view expressed from the procurement management who observe no significant increase in complaints about poor quality translation in the final clinical trial documents,and are happy about reduction in headline ‘out-sourced’ costs,and impressive ‘on-time delivery’metrics. So where does this contradiction come from? 

Well, each CRO has a strong Quality Management System that is set up to make sure that poor translations are corrected, and poor service is mitigated. Most standard operating procedures have two extra steps after the initial translations - a ‘second revision’ by in-house linguists,and also the ethics committee/IRB review.

The CROs also have a team of brilliant hard-working project managers who will make sure that any lack of service and quality in the initial translation is covered by their extra effort. However, this use of the in-house review and extra resource in project management is a significant extra ‘hidden’ cost for the CROs. It also raises quality concerns, as the ‘safety-net’ should not routinely be used to make up for lower quality input and potential time-delays to your trials. 

So what’s the solution? Firstly get your translation suppliers to deliver what you need, not what they want to deliver. This includes them having dedicated PMs to cope with the complexity of clinical trial documentation.

Secondly, monitor the real cost in-house by assessing the‘right first time’ quality of the translated media and ‘all-in’costs of the related processing (including change orders, rush charges and the extra time taken by your in-house resources).

Dr Mark Hooper is a directorat Conversis Medical. For more information visit conversis.com

15th February 2016

Share

Tags

Company Details

Conversis

+44 (0)1869255820

Contact Website

Address:
Bignell Park Barns
Chesterton
Bicester
Oxfordshire
OX26 1TD
United Kingdom

Latest content on this profile

Medical Translations: Why you need to get it right the first time
British and American senior medical executives admit to image and reputation being at risk because of misinterpreted cultural references or linguistic errors.
Conversis
Avoiding PR Disaster: Cultural Customisation

Conversis
10 tips on Transcreation
We have put together a few pointers that you should consider for the process of transcreation.
Conversis
Top 10 tips for Translation in Medical Communications
Accuracy and high-quality should be the most important decision factors when choosing your medical translations partner as there is no room for mistakes or ambiguities.
Conversis
How do you ensure your communication will excite and interest your patients
This is an opinion article on how to keep your patients interested and on board through the full clinical study
Conversis
What it takes to win at Cannes Health Lions
A podcast featuring our Director, Russell Goldsmith, talking with two judges of the Lions Health Awards, Zuleika Burnett, Executive Director for Creative and Innovation at Havas Life Medicom and Martin Hafley, Creative Director at DDB Remedy London, together with a past Bronze winner, Khalid Latiff, Associate Creative Director at Publicis Life Brands Resolute (PLBR), whose company also picked up a Silver and Bronze this year too.
Conversis